West Pharmaceutical Services, Inc. will introduce a new Integrated Solutions Program to help reduce risk, mitigate regulatory complexity and simplify drug development from molecule to market for pharmaceutical partners at and CPhI Worldwide.

West’s Integrated Solutions Program aims to provide customers with a comprehensive approach to drug containment and delivery system development. Available in defined and customized packages, the new offering will combine West’s drug packaging and delivery products with its testing and support services to help meet the needs of the drug product and its delivery system at any stage of development, across all injectable formats. 

“Our customers are under increasing pressure to move new therapies to market quickly while maintaining cost efficiencies – all while enduring increased regulatory scrutiny,” said Karen Flynn, SVP & Chief Commercial Officer, West. ”West’s new Integrated Solutions Program will allow our customers to efficiently leverage our extensive knowledge of primary containment and delivery systems and advanced analytical testing capabilities to manage the regulatory landscape while helping to reduce development and supply risk, accelerate path to market, minimize total cost of ownership and improve the patient experience.”
 
At CPhI Worldwide, West will be highlighted as a finalist in the CPhI Awards for Excellence in Pharma for the categories of Supply Chain, Logistics and Distribution and Corporate Social Responsibility. The CPhI Awards for Excellence in Pharma celebrate companies’ innovation in the drive to push the pharmaceutical industry forward.  

The company will showcase its full portfolio of drug containment and delivery technologies, and will introduce Daikyo’s D Sigma stoppers. Available in Ready-to-Use-Validated (RUV) and Ready-to-Sterilize-Validated (RSV) formats.